Thyroxine-13C6

Modify Date: 2024-04-08 12:00:57

Thyroxine-13C6 structure	Common Name	Thyroxine-13C6
	CAS Number	1217780-14-7	Molecular Weight	782.83
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₉₁₃C₆H₁₁I₄NO₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Thyroxine-13C6

L-Thyroxine-13C6-1 (Levothyroxine-13C6-1; T4-13C6-1) is a 13C labeled L-Thyroxine (HY-18341). L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4)[1][2].

Name	xuiikfgfijcvmt-doezjobusa-n

Description	L-Thyroxine-13C6-1 (Levothyroxine-13C6-1; T4-13C6-1) is a 13C labeled L-Thyroxine (HY-18341). L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4)[1][2].
Related Catalog	Research Areas >> Endocrinology
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [2]. Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323. [3]. Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2(4):144-149.

Description

Related Catalog

Research Areas >> Endocrinology

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.

[2]. Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323.

[3]. Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2(4):144-149.